FINWIRES · TerminalLIVE
FINWIRES

$MPLT

12 stories mentioning MPLTUpdated just now

Every FINWIRES story that references MPLT, newest first.

Sectors

Sector Update: Healthcare Stocks Flat to Lower Premarket Monday

Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.

$ABBV$APGE$DFTX$IBB$MPLT$XLV
Research

UBS Initiates MapLight Therapeutics at Buy With $48 Price Target

MapLight Therapeutics (MPLT) has an average rating of buy and mean price target of $37.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MPLT
Research

UBS Initiates MapLight Therapeutics at Buy With $48 Price Target

MapLight Therapeutics, Inc. (MPLT) has an average rating of buy and mean price target of $36.78, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MPLT
Insider Trading

MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing

Christopher A. Kroeger, Director, Chief Executive Officer, on May 18, 2026, sold 118,235 shares in MapLight Therapeutics (MPLT) for $3,215,000. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,394,094 voting common shares of the company, with 1,394,094 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000012/xslF345X05/form4-05192026_010517.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,024,719, According to a Recent SEC Filing

Vishwas Setia, Chief Financial Officer, on May 04, 2026, sold 36,371 shares in Maplight Therapeutics (MPLT) for $1,024,719. Following the Form 4 filing with the SEC, Setia has control over a total of 356,256 voting common shares of the company, with 356,256 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202125626000008/xslF345X05/form4-05062026_080509.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,427,594, According to a Recent SEC Filing

Erin Pennock Foff, Chief Medical Officer, on May 04, 2026, sold 50,280 shares in Maplight Therapeutics (MPLT) for $1,427,594. Following the Form 4 filing with the SEC, Foff has control over a total of 350,497 voting common shares of the company, with 350,497 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123326000008/xslF345X05/form4-05062026_080507.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,468,251, According to a Recent SEC Filing

James Woodruff Lillie, Chief Scientific Officer, on May 04, 2026, sold 51,707 shares in Maplight Therapeutics (MPLT) for $1,468,251. Following the Form 4 filing with the SEC, Lillie has control over a total of 243,450 voting common shares of the company, with 243,450 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000172874626000008/xslF345X05/form4-05062026_080505.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $388,177, According to a Recent SEC Filing

Kristopher Hanson, General Counsel, on May 04, 2026, sold 13,917 shares in Maplight Therapeutics (MPLT) for $388,177. Following the Form 4 filing with the SEC, Hanson has control over a total of 176,248 voting common shares of the company, with 176,248 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000178997026000008/xslF345X05/form4-05062026_080503.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,412,236, According to a Recent SEC Filing

Christopher A. Kroeger, Director, Chief Executive Officer, on May 04, 2026, sold 49,744 shares in Maplight Therapeutics (MPLT) for $1,412,236. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,682,010 voting common shares of the company, with 1,580,820 shares held directly and 101,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000008/xslF345X05/form4-05062026_080501.xml

$MPLT
Research

HC Wainwright Initiates Coverage on MapLight Therapeutics With Buy Rating, $45 Price Target

MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $34.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $1,347,066, According to a Recent SEC Filing

Anatol Kreitzer, Chief Discovery Officer, on April 27, 2026, sold 45,422 shares in Maplight Therapeutics (MPLT) for $1,347,066. Following the Form 4 filing with the SEC, Kreitzer has control over a total of 211,190 voting common shares of the company, with 211,190 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123826000008/xslF345X05/form4-04292026_040429.xml

$MPLT
Insider Trading

Maplight Therapeutics Insider Sold Shares Worth $2,087,687, According to a Recent SEC Filing

Jonathan Gillis, Chief Administrative and Accounting Officer and Principal Accounting Officer, on April 27, 2026, sold 69,835 shares in Maplight Therapeutics (MPLT) for $2,087,687. Following the Form 4 filing with the SEC, Gillis has control over a total of 181,219 voting common shares of the company, with 181,219 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000170995426000008/xslF345X05/form4-04292026_040431.xml

$MPLT

Track with the FINWIRES app suite

FolioX
FolioX
Track MPLT in your portfolio
WheelAI
WheelAI
Analyze MPLT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MPLT